JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings (NASDAQ:GDRX) following the company’s first-quarter earnings. Gill reaffirmed an Overweight rating on the stock and maintained her $7 price forecast.
The company reported first-quarter 2025 revenue of $203 million (above the $202.21 million estimate), up 3% year-over-year. Adjusted EBITDA rose to $69.8 million, with margins improving to 34.4% from 31.7%. Net income came in at $11.1 million, reversing a $1 million loss in the prior year.
Pharma Manufacturer Solutions’ revenue climbed 17%, while subscription revenue declined 7%, primarily due to the phaseout of the Kroger Savings Club.
Also Read: Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump’s Drug Price Order
GoodRx reaffirmed its full-year 2025 revenue outlook of $810-$840 million and raised its adjusted EBITDA forecast to $273–$287 million, compared to $260.2 million in 2024.
The analyst revised her 2025 revenue estimate slightly downward to $817 million (3% year-over-year growth), citing added ~$5 million in Rite Aid (RAD) headwinds, offset by strength in Pharma Manufacturer Solutions and improved margins.
She increased her adjusted EBITDA projection to $279 million (7% growth), with a 135 basis-point margin expansion to 34.2%. Despite a slight increase in sales and marketing expenses in the second half of 2025, margin strength is expected to persist.
Gill noted the trend of pharmacy costs shifting to consumers and the efforts of pharmacies/PBMs to capture abandoned scripts create a favorable environment for GoodRx’s value proposition.
The analyst anticipates solid growth, execution, and margin expansion with benefits from ISP adoption and increased consumerism in healthcare in 2025 and beyond.
JP Morgan maintained its December 2025 price target of $7, based on a 9x EV/EBITDA multiple on the 2026 forecast of $298 million and a sustained mid-to-high-single-digit EBITDA growth trajectory.
Price Action: GDRX shares are trading lower by 0.88% to $3.93 at last check Monday.
Read Next:
EXCLUSIVE: UnitedHealth Gets Dumped, Why This Asset Manager Says Insurer Is No Longer A Safe Bet
Image by Aria Armoko via Shutterstock
Latest Ratings for GDRX
Date | Firm | Action | From | To |
|---|---|---|---|---|
Mar 2022 | Barclays | Maintains | Overweight | |
Mar 2022 | Morgan Stanley | Maintains | Equal-Weight | |
Mar 2022 | Raymond James | Maintains | Outperform |
View More Analyst Ratings for GDRX
View the Latest Analyst Ratings
“ACTIVE INVESTORS’ SECRET WEAPON” Supercharge Your Stock Market Game with the #1 “news & everything else” trading tool: Benzinga Pro – Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga?
This article GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
